Hot Investor Mandate 4: Pharma Firm Opens New Subsidiary to Seek Cutting Edge Biotech and Medtech Platforms

30 Mar

A pharmaceutical enterprise headquartered in Beijing, China has set up a biotech subsidiary in Massachusetts and is actively seeking cutting-edge life science technologies around the world. The firm makes equity investments of US$2-10 million in Seed to Series B stage companies, while later stages up to pre-IPO may also be considered. For overseas deals, the firm prefers to co-invest with top-tier lead investors. The firm is looking for opportunities across the globe.

The firm is looking for technologies across biopharmaceuticals, medical devices, and healthcare services that are a strategic fit with its portfolio. The firm is most interested in innovative platform technology in small molecule or biologic therapeutics targeting large disease markets in China. The firm considers early-stage companies from seed to Series B stage.

The firm seeks experienced management teams backed by strong, reputable VC firms. The firm typically requests board representation post-investment. The firm prefers to retain China rights, but this is not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: